Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
复制标题
DOI：
10.1002/ajh.23303
复制
发表时间：
2012-11-01
影响因子：
12.8
通讯作者：
List, Alan F.
中科院分区：
文献类型：
--
作者：
Komrokji, Rami S.;Corrales-Yepez, Maria;List, Alan F.
我们假设低白蛋白血症是骨髓增生异常综合征（MDS）患者的独立预后因素。我们分析了2001年1月至2009年12月在Moffitt癌症中心接受治疗的767例患者的记录，以评估出现时血清白蛋白（SA）与总生存期（OS）之间的关系。根据SA浓度（=3.5、3.64.0和>4.0 g/dL）将患者（中位年龄69岁）分为三组。三分之二的患者具有基于国际预后评分系统（IPSS）的低或中1级MDS风险。SA浓度=3.5、3.64.0和>4.0 g/dL的中位生存期分别为11、23和34个月（P < 0.005），而低SA患者的急性髓系白血病进展率最高（=3.5 g/dL）。SA水平对IPSS低风险组和高风险组以及MD Anderson风险模型的预后结果提供了区分。在多变量分析中，经IPSS、年龄、血清铁蛋白和输血依赖校正后，SA是OS的重要独立协变量（风险比= 0.8;95% CI 0.60.9; P = 0.004）。我们的研究结果表明，低白蛋白血症是一种独立的预后生物标志物，可以作为MDS患者疾病生物学或合并症的替代代表。点。j .内科杂志。, 2012年。(c) 2012 Wiley期刊有限公司
We hypothesized that hypoalbuminemia is an independent prognostic factor in patients with myelodysplastic syndromes (MDS). We analyzed records of 767 patients treated at Moffitt Cancer Center between January 2001 and December 2009 to evaluate the relationship between serum albumin (SA) at the time of presentation and overall survival (OS). Patients (median age of 69 years) were stratified into three groups based on SA concentration (=3.5, 3.64.0, and >4.0 g/dL). Two-thirds of the patients had low or intermediate-1 International Prognostic Scoring System (IPSS)-based risk for MDS. Median OS by SA concentration of =3.5, 3.64.0, and >4.0 g/dL was 11, 23, and 34 months, respectively (P < 0.005), whereas rate of acute myeloid leukemia progression was highest in patients with low SA (=3.5 g/dL). The SA level offered prognostic discrimination for outcomes within the lower and higher IPSS risk groups, as well as with the MD Anderson risk model. In multivariable analysis, SA was a significant independent co-variate for OS after adjustment for IPSS, age, serum ferritin, and transfusion dependence (hazard ratio = 0.8; 95% CI 0.60.9; P = 0.004). Our findings indicate that hypoalbuminemia is an independent prognostic biomarker that may serve as a surrogate representative of disease biology or comorbidities in patients with MDS. Am. J. Hematol., 2012. (c) 2012 Wiley Periodicals, Inc.